New stroke drug could give patients up to 24 hours to seek treatment

NCT ID NCT07201688

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a drug called rhTNK-tPA (Mingfule) in people with acute ischemic stroke who can be treated 4.5 to 24 hours after symptoms start. The study plans to enroll 890 participants and will compare the drug to a placebo. The goal is to see if the drug helps patients recover better, as measured by their ability to perform daily activities independently.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rhTNK-tPA (a clot-busting drug)

What this could lead to

If successful, this could allow more stroke patients to receive clot-busting treatment up to 24 hours after symptoms start, potentially reducing disability.

What could go wrong

This is an early Phase 3 trial, so results are not yet proven. There is a risk of bleeding in the brain, a known side effect of clot-busters.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Puyang Oilfield General Hospital

    RECRUITING

    Puyang, Henan, 457001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.